Raynaud's phenomenon (Q71788213)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8923595 AND SRC:MED&resulttype=core&format=json

21 October 2019

review article

1 reference

title

Raynaud's phenomenon (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8923595 AND SRC:MED&resulttype=core&format=json

21 October 2019

author name string

F M Wigley

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8923595 AND SRC:MED&resulttype=core&format=json

21 October 2019

N A Flavahan

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8923595 AND SRC:MED&resulttype=core&format=json

21 October 2019

publication date

1 November 1996

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8923595 AND SRC:MED&resulttype=core&format=json

Rheumatic Diseases Clinics of North America

21 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8923595 AND SRC:MED&resulttype=core&format=json

21 October 2019

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8923595 AND SRC:MED&resulttype=core&format=json

21 October 2019

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8923595 AND SRC:MED&resulttype=core&format=json

21 October 2019

page(s)

765-781

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8923595 AND SRC:MED&resulttype=core&format=json

Reversible cold-induced abnormalities in myocardial perfusion and function in systemic sclerosis

21 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

A standardized finger cooling test for Raynaud's phenomenon: diagnostic value and sex differences

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Venodilation in Raynaud's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study.

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

INTERMITTENT EPOPROSTENOL (PROSTACYCLIN) INFUSION IN PATIENTS WITH RAYNAUD'S SYNDROME

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Validity and reliability of three methods used in the diagnosis of Raynaud's phenomenon. The UK Scleroderma Study Group

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Acute Effects and Mechanism of Action of Ketanserin in Patients with Primary Raynaudʼs Phenomenon

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Deficiency of calcitonin gene-related peptide in Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Vascular alpha-adrenoceptors: from the gene to the human

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Pathogenesis of systemic sclerosis: A vascular hypothesis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Angiotensin converting enzyme inhibitors in Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

International study of ketanserin in Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Total and Capillary Fingertip Blood Flow in Raynaud's Phenomenon

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Role of alpha-adrenoceptor subtypes mediating sympathetic vasoconstriction in human digits

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Controlled multicenter double-blind trial of nicardipine in the treatment of primary Raynaud phenomenon. French Cooperative Multicenter Group for Raynaud Phenomenon, Paris, France

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Digital arteries in patients with scleroderma. Arteriographic and plethysmographic study

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Failure of a pure anti-platelet drug to decrease the number of attacks more than placebo in patients with Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Lower limb amputation secondary to large vessel involvement in scleroderma

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Endothelial Cell Signaling and Endothelial Dysfunction

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

[3H]Thymidine labeling of dermal endothelial cells in scleroderma

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Spinal cord stimulation for the treatment of progressive systemic sclerosis and Raynaud's syndrome

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

The influence of different beta-blocking drugs on the peripheral circulation in Raynaud's phenomenon and in hypertension

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Quantitative measurements of finger blood flow during behavioral treatments for Raynaud's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Blockade of Vasospastic Attacks by α 2 -Adrenergic but Not α 1 -Adrenergic Antagonists in Idiopathic Raynaud’s Disease

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Behavioral treatment of Raynaud's phenomenon in scleroderma

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Cold-induced potentiation of alpha 2-adrenergic vasoconstriction in primary Raynaud's disease

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

The acute effects of cigarette smoking on cutaneous blood flow in smoking and non-smoking subjects with and without Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

The effect of simple warming procedures on finger blood flow in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Anticardiolipin, anticentromere and anti-Scl-70 antibodies in patients with systemic sclerosis and severe digital ischaemia

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Von Willebrand factor, thrombomodulin, thromboxane, beta-thromboglobulin and markers of fibrinolysis in primary Raynaud's phenomenon and systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Endothelin, an endothelial-dependent vasoconstrictor in scleroderma. Enhanced production and profibrotic action

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Overlapping syndromes, undifferentiated connective tissue disease, and other fibrosing conditions.

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Enhanced cholinergic cutaneous vasodilation in Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Characterization of endothelin-binding sites in human skin and their regulation in primary Raynaud's phenomenon and systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Evidence implicating xanthine oxidase and neutrophils in reperfusion-induced microvascular dysfunction

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Long-term outcome of Raynaud's syndrome in a prospectively analyzed patient cohort

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Adrenoceptors in Raynaud's disease.

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Capillary abnormalities, Raynaud's phenomenon, and systemic sclerosis in patients with localized scleroderma

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Letter: Raynaud's phenomenon as side effect of beta-blockers.

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Possible role of endothelin in endothelial regulation of vascular tone

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Roles of peptides and other substances in cotransmission from vascular autonomic and sensory neurons

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Oral limaprost for Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Vascular Disease in Progressive Systemic Sclerosis (Scleroderma)

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Radical microarteriolysis in the treatment of vasospastic disorders of the hand, especially scleroderma

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

The endothelium: its role in scleroderma

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Sequential dermal microvascular and perivascular changes in the development of scleroderma

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Endothelins. Vascular actions and clinical implications

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Diffusing capacity of the lung and nifedipine in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Prolonged effect of CGRP in Raynaud's patients: a double-blind randomised comparison with prostacyclin

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Pulmonary vascular response during Raynaud's phenomenon in progressive systemic sclerosis.

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Prevalence of symptoms of Raynaud's phenomenon in general practice

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Serial nailfold capillary microscopy in primary Raynaud's phenomenon and scleroderma

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Regulation of blood pressure by nitroxidergic nerve

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Successful treatment of Raynaud's phenomenon with limaprost, an oral prostaglandin E1 analogue

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Prevalence of Raynaud phenomenon in the adult population of South Carolina.

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

The effect of cold exposure on diffusing capacity in patients with Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Nicardipine in the treatment of Raynaud's phenomenon. Dissociation of platelet activation from vasospasm

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

The post-occlusive hyperemic response in patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Anticentromere antibody as a predictor of digital ischemic loss in patients with systemic sclerosis

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

The diagnostic value of several immunological tests for anti-nuclear antibody in predicting the development of connective tissue disease in patients presenting with Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Large vessel occlusive disease associated with CREST syndrome and scleroderma

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

Serum endothelin-1 concentrations and cold provocation in primary Raynaud's phenomenon

1 reference

https://api.crossref.org/works/10.1016/S0889-857X(05)70300-8

7 January 2021

10.1016/S0889-857X(05)70300-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:8923595 AND SRC:MED&resulttype=core&format=json

21 October 2019

1 reference